HC Wainwright Estimates Krystal Biotech Q1 Earnings

Krystal Biotech, Inc. (NASDAQ:KRYS) – Investment analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Krystal Biotech in a research note issued on Wednesday, February 19th. HC Wainwright analyst J. Pantginis forecasts that the company will earn $1.56 per share for the quarter. HC Wainwright has a “Buy” rating and a $221.00 price objective on the stock. The consensus estimate for Krystal Biotech’s current full-year earnings is $6.14 per share. HC Wainwright also issued estimates for Krystal Biotech’s Q2 2025 earnings at $1.74 EPS, Q3 2025 earnings at $1.98 EPS, Q4 2025 earnings at $2.24 EPS, FY2025 earnings at $6.97 EPS, FY2026 earnings at $6.23 EPS, FY2027 earnings at $8.49 EPS and FY2028 earnings at $8.78 EPS.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings results on Monday, February 24th. The company reported $1.52 earnings per share for the quarter, topping the consensus estimate of $1.29 by $0.23. The company had revenue of $91.10 million during the quarter, compared to the consensus estimate of $91.35 million. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The firm’s quarterly revenue was up 116.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.30 EPS.

Several other research analysts also recently weighed in on the company. Chardan Capital increased their price target on Krystal Biotech from $212.00 to $218.00 and gave the stock a “buy” rating in a research note on Thursday, February 20th. Citigroup increased their price target on Krystal Biotech from $206.00 to $215.00 and gave the stock a “neutral” rating in a research note on Thursday, February 20th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price objective on shares of Krystal Biotech in a report on Thursday, February 20th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Krystal Biotech has a consensus rating of “Buy” and an average price target of $210.00.

Krystal Biotech Stock Performance

KRYS stock opened at $181.10 on Monday. The company has a market capitalization of $5.22 billion, a price-to-earnings ratio of 60.57 and a beta of 0.84. Krystal Biotech has a fifty-two week low of $125.85 and a fifty-two week high of $219.34. The stock has a fifty day moving average of $158.24 and a 200-day moving average of $175.31.

Insider Buying and Selling

In related news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction dated Friday, December 13th. The stock was sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the sale, the insider now owns 1,475,882 shares of the company’s stock, valued at approximately $243,195,835.96. This represents a 1.67 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 14.10% of the stock is currently owned by insiders.

Institutional Trading of Krystal Biotech

A number of institutional investors have recently added to or reduced their stakes in the stock. Creative Planning raised its holdings in shares of Krystal Biotech by 64.9% in the 3rd quarter. Creative Planning now owns 5,744 shares of the company’s stock valued at $1,046,000 after acquiring an additional 2,260 shares in the last quarter. Blue Trust Inc. raised its holdings in shares of Krystal Biotech by 242.4% in the 3rd quarter. Blue Trust Inc. now owns 582 shares of the company’s stock valued at $107,000 after acquiring an additional 412 shares in the last quarter. Mount Yale Investment Advisors LLC purchased a new stake in shares of Krystal Biotech in the 3rd quarter valued at about $187,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Krystal Biotech by 21.8% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,039 shares of the company’s stock valued at $184,000 after acquiring an additional 186 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its holdings in shares of Krystal Biotech by 64.8% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,526 shares of the company’s stock valued at $1,006,000 after acquiring an additional 2,172 shares in the last quarter. Hedge funds and other institutional investors own 86.29% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).